225
Views
18
CrossRef citations to date
0
Altmetric
Review

A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy

, , &
Pages 37-46 | Published online: 15 Feb 2011

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (6)

Giorgio Walter Canonica, Giorgio Lorenzo Colombo, Paola Rogliani, Pierachille Santus, Claudia Pitotti, Sergio Di Matteo, Chiara Martinotti & Giacomo Matteo Bruno. (2020) Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study. Risk Management and Healthcare Policy 13, pages 43-53.
Read now
Giuseppe La Torre, Alice Mannocci, Rosella Saulle, Vittoria Colamesta, Angela Meggiolaro, Daniele Mipatrini & Alessandra Sinopoli. (2016) Economic evaluation of HBV vaccination: A systematic review of recent publications (2000–2013). Human Vaccines & Immunotherapeutics 12:9, pages 2299-2311.
Read now
Giorgio L Colombo, Sergio Di Matteo, Andrea Antinori, Massimo Medaglia, Silvia Murachelli & Giuliano Rizzardini. (2013) Economic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines. ClinicoEconomics and Outcomes Research 5, pages 489-496.
Read now
Giuliano Rizzardini, Paolo Bonfanti, Laura Carenzi, Massimo Coen, Giovanna Orlando, Sergio Di Matteo & Giorgio L Colombo. (2012) Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy. Therapeutics and Clinical Risk Management 8, pages 377-384.
Read now
Giorgio L Colombo, Sergio Di Matteo & Giacomo Bruno. (2012) Acamprosate in the treatment of alcoholism: a budget impact analysis for the National Health Service in Italy. Substance Abuse and Rehabilitation 3, pages 73-79.
Read now
Giorgio L Colombo, Vincenzo Colangeli, Antonio Di Biagio, Sergio Di Matteo, Claudio Viscoli & Pierluigi Viale. (2011) Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. ClinicoEconomics and Outcomes Research 3, pages 197-205.
Read now

Articles from other publishers (12)

Peng Lu, Tingrui Zhang, Yali Ren, Huanan Rao, Jieting Lei, Guiying Zhao, Miao Wang, Daoyin Gong & Zhixing Cao. (2023) A Literature Review on the Antiviral Mechanism of Luteolin. Natural Product Communications 18:4, pages 1934578X2311715.
Crossref
Peter Wigfield, Urbano Sbarigia, Mahmoud Hashim, Talitha Vincken & Bart Heeg. (2019) Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review. PharmacoEconomics - Open 4:3, pages 403-418.
Crossref
Feng Tian, Sherilyn K. D. Houle, Mhd. Wasem Alsabbagh & William W. L. Wong. (2019) Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada. PharmacoEconomics 38:2, pages 181-192.
Crossref
M. Ruggeri, M. Basile, S. Coretti, C. Drago & A. Cicchetti. (2017) Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy. Applied Health Economics and Health Policy 15:4, pages 479-490.
Crossref
Ashish Goyal & John M. Murray. (2016) Cost-Effectiveness of Peg-Interferon, Interferon and Oral Nucleoside Analogues in the Treatment of Chronic Hepatitis B and D Infections in China. Clinical Drug Investigation 36:8, pages 637-648.
Crossref
Mehlika Toy. (2013) Cost-effectiveness of viral hepatitis B & C treatment. Best Practice & Research Clinical Gastroenterology 27:6, pages 973-985.
Crossref
Sergio Iannazzo, Maria De Francesco, Barbara Coco, Maurizia Rossana Brunetto, Radovan Tomic, Davide Paolini, Giulio Palmieri & Ferruccio Bonino. (2013) Impatto sul budget di un trattamento personalizzato dell’epatite B cronica HBeAg-negativa in Italia mediante peg-interferone alfa-2a associato alla stopping-rule alla 12a settimanaBudget impact of an individualized treatment for HBeAg-negative chronic hepatitis B in Italy with peg-interferon alpha-2a combined to 12 weeks’ stopping-rule. PharmacoEconomics Italian Research Articles 15:3, pages 123-130.
Crossref
Gustavo Laine Araujo de Oliveira, Alessandra Maciel Almeida, Anderson Lourenco da Silva, Cristina Mariano Ruas Brandao, Eli Iola Gurgel Andrade, Mariangela Leal Cherchiglia & Francisco de Assis Acurcio. (2013) Antivirais incorporados no Brasil para hepatite B cronica: analise de custo-efetividade. Revista de Saúde Pública 47:4, pages 769-780.
Crossref
Sergio Iannazzo, Barbara Coco, Maurizia R Brunetto, Francesca Rossetti, Antonietta Caputo, Andrea Latour, Belen Espinos & Ferruccio Bonino. (2013) Individualized Treatment of Hbeag-Negative Chronic Hepatitis B Using Pegylated Interferon-α2A as First-Line and Week-12 HBV Dna/Hbsag Stopping Rule: A Cost-Effectiveness Analysis. Antiviral Therapy 18:4, pages 1-11.
Crossref
Seyfettin Koklu, Murat Taner Gulsen, Yasar Tuna, Hayretdin Koklu, Osman Yuksel, Baris Yilmaz, Cetin Karaca, Huseyin Ataseven, Rahmet Guner, Metin Kucukazman, Cem Kockar, Mehmet Demir, Orhan Kursat Poyrazoglu, Mehmet Ibis, Tugrul Purnak, Sezgin Etgul, Erhan Alkan, Sahin Coban, Suut Gokturk, Murat Biyik, Ozlem Baykal, Omer Basar, Nimet Koklu, Gonca Tatar & Halis Simsek. (2013) Lamivudine Treatment Failure Risks in Chronic Hepatitis B Patients with Low Viral Load. Digestion 88:4, pages 266-271.
Crossref
María Buti, Itziar Oyagüez, Virginia Lozano & Miguel A. Casado. (2012) Cost Effectiveness of First-Line Oral Antiviral Therapies for Chronic Hepatitis B. PharmacoEconomics 31:1, pages 63-75.
Crossref
David Vanness, Ian Joseph, Rui Marinho, Jorge Areias, Armando Carvalho, Guilherme Macedo, Leopoldo Matos, Beatriz Rodrigues, José Velosa, Filipa Aragão, Julian Perelman & Nikhil Revankar. (2012) Custo-utilidade do tenofovir comparado com entecavir no tratamento em primeira linha da hepatite B crónica. GE Jornal Português de Gastrenterologia 19:4, pages 170-182.
Crossref